Atualização sobre osteossarcoma convencional

Resumo

O osteossarcoma convencional é um tumor de alto grau de malignidade caracterizado pela produção de matriz osteóide pelos osteoblastos malignos. Tipicamente acomete ossos longos de crianças e adolescentes e o tratamento inclui abordagem sistêmica com quimioterapia e abordagem cirúrgica local com ressecção ampla. Avanços recentes nos conceitos oncológicos, de imagem, planejamento cirúrgico e protocolos de tratamento oncológico permitem uma melhora na sobrevida e maior taxa de preservação de membros. Este artigo aborda o estado atual relativo a incidência, patologia, tratamento e prognóstico do osteossarcoma convencional de alto grau.

Palavras-chave

neoplasias - osteossarcoma - sarcomas

Publication History

Received: 26 July 2022

Accepted: 27 March 2023

Article published online:
29 January 2024

• Referências

• 1 Flanagan AM, Blay JY, Bovée JVMG. et al. Bone tumours: Introduction. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 340-444
• 2 Baumhoer D, Böhling TO, Cates JMM. et al. Osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 403-409
• 3 Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer 2022; 128 (11) 2107-2118
• 4 Mansur SF, Barbosa CSP, Miranda D. et al. Sarcoma osteogênico - Estudo retrospectivo epidemiológico de 184 casos diagnosticados em Belo Horizonte, Minas Gerais. Rev Bras Ortop 1996; 31 (12) 995-1000
• 5 Castro HC, Ribeiro KCB, Bruniera P. Osteossarcoma: Experiência do Serviço de Oncologia Pediátrica da Santa Casa de Misericórdia de São Paulo. Rev Bras Ortop 2008; 43 (04) 108-115
• 6 Jadão FRS, Lima LS, Lopes JAS, Ribeiro MB. Avaliação dos fatores prognósticos e sobrevida de pacientes com Osteossarcoma atendidos em um Hospital Filantrópico de Teresina (PI), Brasil. Rev Bras Ortop 2013; 48 (01) 87-91
• 7 Presti PF, Macedo CRD, Caran EM, Rodrigues AHD, Petrilli AS. Estudo epidemiológico de câncer na adolescência em centro de referência. Rev Paul Pediatr 2012; 30 (02) 210-216
• 8 Yoshida A, Bredella MA, Gambarotti M, Sumathi VP. Low-grade central osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 400-402
• 9 Guedes A, Oliveira MBDR, Costa FM, de Melo AS. Updating on bone and soft tissue sarcomas staging. Rev Bras Ortop 2021; 56 (04) 411-418
• 10 Guedes A, Oliveira MBR, Melo AS, Carmo CCM. Update in imaging evaluation of bone and soft tissue sarcomas. [Published online: 2021-11-11] Rev Bras Ortop. Available from: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0041-1736569
• 11 Wang J, Nord KH, O'Donnel PG, Yoshida A. Parosteal osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 410-413
• 12 Binitie O, Morris CD. Conventional Osteoblastic Osteosarcoma. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthoopaedic Surgeons; 2021: 169-180
• 13 Brookes MJ, Chan CD, Baljer B. et al. Surgical Advances in Osteosarcoma. Cancers (Basel) 2021; 13 (03) 388
• 14 Ferguson PC, McLaughlin CE, Griffin AM, Bell RS, Deheshi BM, Wunder JS. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma. J Surg Oncol 2010; 102 (02) 120-124
• 15 He F, Zhang W, Shen Y. et al. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg 2016; 36 ( Pt A ): 283-292
• 16 Lawrenz JM, Mesko NW. General Principles of Wide Resection of Bone Tumors. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthopaedic Surgeons; Wolters Kluwer; 2021: 407-422
• 17 Loh AHP, Wu H, Bahrami A. et al. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. Pediatr Blood Cancer 2015; 62 (02) 246-251
• 18 Malawer MM, Wittig JC, Bickels J, Wiesel SW. Operative Techniques in Orthopaedic Surgical Oncology. 2nd ed. Philadelphia: Wolters Kluwer; 2016
• 19 Ayerza MA, Farfalli GL, Aponte-Tinao L, Muscolo DL. Does increased rate of limb-sparing surgery affect survival in osteosarcoma?. Clin Orthop Relat Res 2010; 468 (11) 2854-2859
• 20 Aponte-Tinao LA, Ayerza MA, Albergo JI, Farfalli GL. Do Massive Allograft Reconstructions for Tumors of the Femur and Tibia Survive 10 or More Years after Implantation?. Clin Orthop Relat Res 2020; 478 (03) 517-524
• 21 Hamed Kassem Abdelaal A, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Tsuchiya H. Epiphyseal Sparing and Reconstruction by Frozen Bone Autograft after Malignant Bone Tumor Resection in Children. Sarcoma 2015; 2015: 892141
• 22 Gross SW. The Classic: sarcoma of the long bones: based upon a study of one hundred and sixty-five cases. 1879. Clin Orthop Relat Res 2005; 438 (438) 9-14
• 23 Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res 1982; (167) 250-254
• 24 Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 1978; 53 (11) 695-700
• 25 Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5 (01) 21-26
• 26 Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37 (01) 1-11
• 27 Bielack SS, Smeland S, Whelan JS. et al; EURAMOS-1 investigators. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. [published correction appears in J Clin Oncol 2016;34(33):4059] J Clin Oncol 2015; 33 (20) 2279-2287
• 28 Ward WG, Mikaelian K, Dorey F. et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994; 12 (09) 1849-1858
• 29 Akazawa R, Umeda K, Saida S. et al. Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. Jpn J Clin Oncol 2020; 50 (08) 948-952
• 30 Senerchia AA, Macedo CR, Ferman S. et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment. Cancer 2017; 123 (06) 1003-1010
• 31 Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. [published correction appears in J Clin Oncol 2001;19(9):2583] J Clin Oncol 2001; 19 (06) 1839-1847
• 32 Kiany S, Gordon N. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. Methods Mol Biol 2016; 1441: 285-295
• 33 Gordon N, Felix K, Daw NC. Aerosolized Chemotherapy for Osteosarcoma. Adv Exp Med Biol 2020; 1257: 67-73
• 34 Chen Y, Liu R, Wang W. et al. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res 2021; 169: 105684
• 35 Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021; 500: 1-10
• 36 Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer 2016; 63 (10) 1780-1785
• 37 Wang Y, Yu W, Zhu J. et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 2019; 38 (01) 168